ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Peptide CDMO Pharmaceutical Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-28B13805
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Peptide CDMO Pharmaceutical Market Research Report 2023
BUY CHAPTERS

Global Peptide CDMO Pharmaceutical Market Research Report 2025

Code: QYRE-Auto-28B13805
Report
May 2025
Pages:107
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
AmbioPharm
Auspep
Bachem
CPC Scientific
Creative Peptides
Chinese Peptide
CSBIO
Corden Pharma
PolyPeptide
Peptide Institute
Pepscan
ALMAC
Vivitide
Creosalus
ScinoPharm
Senn Chemicals
Belyntic
Numaferm
Provepharm Life Solutions
Enzene Biosciences
Piramal Pharma
Bcn Peptide
Ferring Pharma
Hybio Pharmaceutical

Peptide CDMO Pharmaceutical Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Peptide CDMO Pharmaceutical Market

Peptide CDMO Pharmaceutical Market

The global market for Peptide CDMO Pharmaceutical was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Peptide CDMO Pharmaceutical, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide CDMO Pharmaceutical.
The Peptide CDMO Pharmaceutical market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Peptide CDMO Pharmaceutical market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peptide CDMO Pharmaceutical companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Peptide CDMO Pharmaceutical Market Report

Report Metric Details
Report Name Peptide CDMO Pharmaceutical Market
CAGR 5%
Segment by Type
  • Liquid-phase Peptide Synthesis（LPPS）
  • Solid-phase Peptide Synthesis（SPPS）
  • Mixed Phase
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Ambiopharm, Auspep, Bachem, Bcn Peptide, Cpc Scientific, Creative Peptides, Chinese Peptide, Csbio, Corden Pharma, Polypeptide, Hybio Pharmaceutical, Peptide Institute, Pepscan, Almac, Vivitide, Creosalus Inc, Scinopharm, Senn Chemicals, Belyntic, Ferring Pharma, Numaferm, Provepharm Life Solutions, Enzene Biosciences, Piramal Pharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Peptide CDMO Pharmaceutical company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Peptide CDMO Pharmaceutical Market report?

Ans: The main players in the Peptide CDMO Pharmaceutical Market are Ambiopharm, Auspep, Bachem, Bcn Peptide, Cpc Scientific, Creative Peptides, Chinese Peptide, Csbio, Corden Pharma, Polypeptide, Hybio Pharmaceutical, Peptide Institute, Pepscan, Almac, Vivitide, Creosalus Inc, Scinopharm, Senn Chemicals, Belyntic, Ferring Pharma, Numaferm, Provepharm Life Solutions, Enzene Biosciences, Piramal Pharma

What are the Application segmentation covered in the Peptide CDMO Pharmaceutical Market report?

Ans: The Applications covered in the Peptide CDMO Pharmaceutical Market report are Peptide Supplements, Peptide Vaccines, Others

What are the Type segmentation covered in the Peptide CDMO Pharmaceutical Market report?

Ans: The Types covered in the Peptide CDMO Pharmaceutical Market report are Liquid-phase Peptide Synthesis（LPPS）, Solid-phase Peptide Synthesis（SPPS）, Mixed Phase

Recommended Reports

CDMO Market Trends

Diagnostics & Therapy

Digital Health Software

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide CDMO Pharmaceutical Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Liquid-phase Peptide Synthesis（LPPS）
1.2.3 Solid-phase Peptide Synthesis（SPPS）
1.2.4 Mixed Phase
1.3 Market by Application
1.3.1 Global Peptide CDMO Pharmaceutical Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Peptide Supplements
1.3.3 Peptide Vaccines
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peptide CDMO Pharmaceutical Market Perspective (2020-2031)
2.2 Global Peptide CDMO Pharmaceutical Growth Trends by Region
2.2.1 Global Peptide CDMO Pharmaceutical Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Peptide CDMO Pharmaceutical Historic Market Size by Region (2020-2025)
2.2.3 Peptide CDMO Pharmaceutical Forecasted Market Size by Region (2026-2031)
2.3 Peptide CDMO Pharmaceutical Market Dynamics
2.3.1 Peptide CDMO Pharmaceutical Industry Trends
2.3.2 Peptide CDMO Pharmaceutical Market Drivers
2.3.3 Peptide CDMO Pharmaceutical Market Challenges
2.3.4 Peptide CDMO Pharmaceutical Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peptide CDMO Pharmaceutical Players by Revenue
3.1.1 Global Top Peptide CDMO Pharmaceutical Players by Revenue (2020-2025)
3.1.2 Global Peptide CDMO Pharmaceutical Revenue Market Share by Players (2020-2025)
3.2 Global Peptide CDMO Pharmaceutical Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Peptide CDMO Pharmaceutical Revenue
3.4 Global Peptide CDMO Pharmaceutical Market Concentration Ratio
3.4.1 Global Peptide CDMO Pharmaceutical Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide CDMO Pharmaceutical Revenue in 2024
3.5 Global Key Players of Peptide CDMO Pharmaceutical Head office and Area Served
3.6 Global Key Players of Peptide CDMO Pharmaceutical, Product and Application
3.7 Global Key Players of Peptide CDMO Pharmaceutical, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Peptide CDMO Pharmaceutical Breakdown Data by Type
4.1 Global Peptide CDMO Pharmaceutical Historic Market Size by Type (2020-2025)
4.2 Global Peptide CDMO Pharmaceutical Forecasted Market Size by Type (2026-2031)
5 Peptide CDMO Pharmaceutical Breakdown Data by Application
5.1 Global Peptide CDMO Pharmaceutical Historic Market Size by Application (2020-2025)
5.2 Global Peptide CDMO Pharmaceutical Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Peptide CDMO Pharmaceutical Market Size (2020-2031)
6.2 North America Peptide CDMO Pharmaceutical Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Peptide CDMO Pharmaceutical Market Size by Country (2020-2025)
6.4 North America Peptide CDMO Pharmaceutical Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peptide CDMO Pharmaceutical Market Size (2020-2031)
7.2 Europe Peptide CDMO Pharmaceutical Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Peptide CDMO Pharmaceutical Market Size by Country (2020-2025)
7.4 Europe Peptide CDMO Pharmaceutical Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peptide CDMO Pharmaceutical Market Size (2020-2031)
8.2 Asia-Pacific Peptide CDMO Pharmaceutical Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Peptide CDMO Pharmaceutical Market Size by Region (2020-2025)
8.4 Asia-Pacific Peptide CDMO Pharmaceutical Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Peptide CDMO Pharmaceutical Market Size (2020-2031)
9.2 Latin America Peptide CDMO Pharmaceutical Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Peptide CDMO Pharmaceutical Market Size by Country (2020-2025)
9.4 Latin America Peptide CDMO Pharmaceutical Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peptide CDMO Pharmaceutical Market Size (2020-2031)
10.2 Middle East & Africa Peptide CDMO Pharmaceutical Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Peptide CDMO Pharmaceutical Market Size by Country (2020-2025)
10.4 Middle East & Africa Peptide CDMO Pharmaceutical Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Ambiopharm
11.1.1 Ambiopharm Company Details
11.1.2 Ambiopharm Business Overview
11.1.3 Ambiopharm Peptide CDMO Pharmaceutical Introduction
11.1.4 Ambiopharm Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.1.5 Ambiopharm Recent Development
11.2 Auspep
11.2.1 Auspep Company Details
11.2.2 Auspep Business Overview
11.2.3 Auspep Peptide CDMO Pharmaceutical Introduction
11.2.4 Auspep Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.2.5 Auspep Recent Development
11.3 Bachem
11.3.1 Bachem Company Details
11.3.2 Bachem Business Overview
11.3.3 Bachem Peptide CDMO Pharmaceutical Introduction
11.3.4 Bachem Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.3.5 Bachem Recent Development
11.4 Bcn Peptide
11.4.1 Bcn Peptide Company Details
11.4.2 Bcn Peptide Business Overview
11.4.3 Bcn Peptide Peptide CDMO Pharmaceutical Introduction
11.4.4 Bcn Peptide Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.4.5 Bcn Peptide Recent Development
11.5 Cpc Scientific
11.5.1 Cpc Scientific Company Details
11.5.2 Cpc Scientific Business Overview
11.5.3 Cpc Scientific Peptide CDMO Pharmaceutical Introduction
11.5.4 Cpc Scientific Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.5.5 Cpc Scientific Recent Development
11.6 Creative Peptides
11.6.1 Creative Peptides Company Details
11.6.2 Creative Peptides Business Overview
11.6.3 Creative Peptides Peptide CDMO Pharmaceutical Introduction
11.6.4 Creative Peptides Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.6.5 Creative Peptides Recent Development
11.7 Chinese Peptide
11.7.1 Chinese Peptide Company Details
11.7.2 Chinese Peptide Business Overview
11.7.3 Chinese Peptide Peptide CDMO Pharmaceutical Introduction
11.7.4 Chinese Peptide Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.7.5 Chinese Peptide Recent Development
11.8 Csbio
11.8.1 Csbio Company Details
11.8.2 Csbio Business Overview
11.8.3 Csbio Peptide CDMO Pharmaceutical Introduction
11.8.4 Csbio Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.8.5 Csbio Recent Development
11.9 Corden Pharma
11.9.1 Corden Pharma Company Details
11.9.2 Corden Pharma Business Overview
11.9.3 Corden Pharma Peptide CDMO Pharmaceutical Introduction
11.9.4 Corden Pharma Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.9.5 Corden Pharma Recent Development
11.10 Polypeptide
11.10.1 Polypeptide Company Details
11.10.2 Polypeptide Business Overview
11.10.3 Polypeptide Peptide CDMO Pharmaceutical Introduction
11.10.4 Polypeptide Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.10.5 Polypeptide Recent Development
11.11 Hybio Pharmaceutical
11.11.1 Hybio Pharmaceutical Company Details
11.11.2 Hybio Pharmaceutical Business Overview
11.11.3 Hybio Pharmaceutical Peptide CDMO Pharmaceutical Introduction
11.11.4 Hybio Pharmaceutical Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.11.5 Hybio Pharmaceutical Recent Development
11.12 Peptide Institute
11.12.1 Peptide Institute Company Details
11.12.2 Peptide Institute Business Overview
11.12.3 Peptide Institute Peptide CDMO Pharmaceutical Introduction
11.12.4 Peptide Institute Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.12.5 Peptide Institute Recent Development
11.13 Pepscan
11.13.1 Pepscan Company Details
11.13.2 Pepscan Business Overview
11.13.3 Pepscan Peptide CDMO Pharmaceutical Introduction
11.13.4 Pepscan Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.13.5 Pepscan Recent Development
11.14 Almac
11.14.1 Almac Company Details
11.14.2 Almac Business Overview
11.14.3 Almac Peptide CDMO Pharmaceutical Introduction
11.14.4 Almac Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.14.5 Almac Recent Development
11.15 Vivitide
11.15.1 Vivitide Company Details
11.15.2 Vivitide Business Overview
11.15.3 Vivitide Peptide CDMO Pharmaceutical Introduction
11.15.4 Vivitide Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.15.5 Vivitide Recent Development
11.16 Creosalus Inc
11.16.1 Creosalus Inc Company Details
11.16.2 Creosalus Inc Business Overview
11.16.3 Creosalus Inc Peptide CDMO Pharmaceutical Introduction
11.16.4 Creosalus Inc Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.16.5 Creosalus Inc Recent Development
11.17 Scinopharm
11.17.1 Scinopharm Company Details
11.17.2 Scinopharm Business Overview
11.17.3 Scinopharm Peptide CDMO Pharmaceutical Introduction
11.17.4 Scinopharm Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.17.5 Scinopharm Recent Development
11.18 Senn Chemicals
11.18.1 Senn Chemicals Company Details
11.18.2 Senn Chemicals Business Overview
11.18.3 Senn Chemicals Peptide CDMO Pharmaceutical Introduction
11.18.4 Senn Chemicals Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.18.5 Senn Chemicals Recent Development
11.19 Belyntic
11.19.1 Belyntic Company Details
11.19.2 Belyntic Business Overview
11.19.3 Belyntic Peptide CDMO Pharmaceutical Introduction
11.19.4 Belyntic Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.19.5 Belyntic Recent Development
11.20 Ferring Pharma
11.20.1 Ferring Pharma Company Details
11.20.2 Ferring Pharma Business Overview
11.20.3 Ferring Pharma Peptide CDMO Pharmaceutical Introduction
11.20.4 Ferring Pharma Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.20.5 Ferring Pharma Recent Development
11.21 Numaferm
11.21.1 Numaferm Company Details
11.21.2 Numaferm Business Overview
11.21.3 Numaferm Peptide CDMO Pharmaceutical Introduction
11.21.4 Numaferm Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.21.5 Numaferm Recent Development
11.22 Hybio Pharmaceutical
11.22.1 Hybio Pharmaceutical Company Details
11.22.2 Hybio Pharmaceutical Business Overview
11.22.3 Hybio Pharmaceutical Peptide CDMO Pharmaceutical Introduction
11.22.4 Hybio Pharmaceutical Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.22.5 Hybio Pharmaceutical Recent Development
11.23 Provepharm Life Solutions
11.23.1 Provepharm Life Solutions Company Details
11.23.2 Provepharm Life Solutions Business Overview
11.23.3 Provepharm Life Solutions Peptide CDMO Pharmaceutical Introduction
11.23.4 Provepharm Life Solutions Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.23.5 Provepharm Life Solutions Recent Development
11.24 Enzene Biosciences
11.24.1 Enzene Biosciences Company Details
11.24.2 Enzene Biosciences Business Overview
11.24.3 Enzene Biosciences Peptide CDMO Pharmaceutical Introduction
11.24.4 Enzene Biosciences Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.24.5 Enzene Biosciences Recent Development
11.25 Piramal Pharma
11.25.1 Piramal Pharma Company Details
11.25.2 Piramal Pharma Business Overview
11.25.3 Piramal Pharma Peptide CDMO Pharmaceutical Introduction
11.25.4 Piramal Pharma Revenue in Peptide CDMO Pharmaceutical Business (2020-2025)
11.25.5 Piramal Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
AmbioPharm
Auspep
Bachem
CPC Scientific
Creative Peptides
Chinese Peptide
CSBIO
Corden Pharma
PolyPeptide
Peptide Institute
Pepscan
ALMAC
Vivitide
Creosalus
ScinoPharm
Senn Chemicals
Belyntic
Numaferm
Provepharm Life Solutions
Enzene Biosciences
Piramal Pharma
Bcn Peptide
Ferring Pharma
Hybio Pharmaceutical
List of Tables
 Table 1. Global Peptide CDMO Pharmaceutical Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Liquid-phase Peptide Synthesis（LPPS）
 Table 3. Key Players of Solid-phase Peptide Synthesis（SPPS）
 Table 4. Key Players of Mixed Phase
 Table 5. Global Peptide CDMO Pharmaceutical Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Peptide CDMO Pharmaceutical Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Peptide CDMO Pharmaceutical Market Size by Region (2020-2025) & (US$ Million)
 Table 8. Global Peptide CDMO Pharmaceutical Market Share by Region (2020-2025)
 Table 9. Global Peptide CDMO Pharmaceutical Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 10. Global Peptide CDMO Pharmaceutical Market Share by Region (2026-2031)
 Table 11. Peptide CDMO Pharmaceutical Market Trends
 Table 12. Peptide CDMO Pharmaceutical Market Drivers
 Table 13. Peptide CDMO Pharmaceutical Market Challenges
 Table 14. Peptide CDMO Pharmaceutical Market Restraints
 Table 15. Global Peptide CDMO Pharmaceutical Revenue by Players (2020-2025) & (US$ Million)
 Table 16. Global Peptide CDMO Pharmaceutical Market Share by Players (2020-2025)
 Table 17. Global Top Peptide CDMO Pharmaceutical Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide CDMO Pharmaceutical as of 2024)
 Table 18. Ranking of Global Top Peptide CDMO Pharmaceutical Companies by Revenue (US$ Million) in 2024
 Table 19. Global 5 Largest Players Market Share by Peptide CDMO Pharmaceutical Revenue (CR5 and HHI) & (2020-2025)
 Table 20. Global Key Players of Peptide CDMO Pharmaceutical, Headquarters and Area Served
 Table 21. Global Key Players of Peptide CDMO Pharmaceutical, Product and Application
 Table 22. Global Key Players of Peptide CDMO Pharmaceutical, Date of Enter into This Industry
 Table 23. Mergers & Acquisitions, Expansion Plans
 Table 24. Global Peptide CDMO Pharmaceutical Market Size by Type (2020-2025) & (US$ Million)
 Table 25. Global Peptide CDMO Pharmaceutical Revenue Market Share by Type (2020-2025)
 Table 26. Global Peptide CDMO Pharmaceutical Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 27. Global Peptide CDMO Pharmaceutical Revenue Market Share by Type (2026-2031)
 Table 28. Global Peptide CDMO Pharmaceutical Market Size by Application (2020-2025) & (US$ Million)
 Table 29. Global Peptide CDMO Pharmaceutical Revenue Market Share by Application (2020-2025)
 Table 30. Global Peptide CDMO Pharmaceutical Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 31. Global Peptide CDMO Pharmaceutical Revenue Market Share by Application (2026-2031)
 Table 32. North America Peptide CDMO Pharmaceutical Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 33. North America Peptide CDMO Pharmaceutical Market Size by Country (2020-2025) & (US$ Million)
 Table 34. North America Peptide CDMO Pharmaceutical Market Size by Country (2026-2031) & (US$ Million)
 Table 35. Europe Peptide CDMO Pharmaceutical Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. Europe Peptide CDMO Pharmaceutical Market Size by Country (2020-2025) & (US$ Million)
 Table 37. Europe Peptide CDMO Pharmaceutical Market Size by Country (2026-2031) & (US$ Million)
 Table 38. Asia-Pacific Peptide CDMO Pharmaceutical Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 39. Asia-Pacific Peptide CDMO Pharmaceutical Market Size by Region (2020-2025) & (US$ Million)
 Table 40. Asia-Pacific Peptide CDMO Pharmaceutical Market Size by Region (2026-2031) & (US$ Million)
 Table 41. Latin America Peptide CDMO Pharmaceutical Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Latin America Peptide CDMO Pharmaceutical Market Size by Country (2020-2025) & (US$ Million)
 Table 43. Latin America Peptide CDMO Pharmaceutical Market Size by Country (2026-2031) & (US$ Million)
 Table 44. Middle East & Africa Peptide CDMO Pharmaceutical Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 45. Middle East & Africa Peptide CDMO Pharmaceutical Market Size by Country (2020-2025) & (US$ Million)
 Table 46. Middle East & Africa Peptide CDMO Pharmaceutical Market Size by Country (2026-2031) & (US$ Million)
 Table 47. Ambiopharm Company Details
 Table 48. Ambiopharm Business Overview
 Table 49. Ambiopharm Peptide CDMO Pharmaceutical Product
 Table 50. Ambiopharm Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 51. Ambiopharm Recent Development
 Table 52. Auspep Company Details
 Table 53. Auspep Business Overview
 Table 54. Auspep Peptide CDMO Pharmaceutical Product
 Table 55. Auspep Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 56. Auspep Recent Development
 Table 57. Bachem Company Details
 Table 58. Bachem Business Overview
 Table 59. Bachem Peptide CDMO Pharmaceutical Product
 Table 60. Bachem Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 61. Bachem Recent Development
 Table 62. Bcn Peptide Company Details
 Table 63. Bcn Peptide Business Overview
 Table 64. Bcn Peptide Peptide CDMO Pharmaceutical Product
 Table 65. Bcn Peptide Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 66. Bcn Peptide Recent Development
 Table 67. Cpc Scientific Company Details
 Table 68. Cpc Scientific Business Overview
 Table 69. Cpc Scientific Peptide CDMO Pharmaceutical Product
 Table 70. Cpc Scientific Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 71. Cpc Scientific Recent Development
 Table 72. Creative Peptides Company Details
 Table 73. Creative Peptides Business Overview
 Table 74. Creative Peptides Peptide CDMO Pharmaceutical Product
 Table 75. Creative Peptides Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 76. Creative Peptides Recent Development
 Table 77. Chinese Peptide Company Details
 Table 78. Chinese Peptide Business Overview
 Table 79. Chinese Peptide Peptide CDMO Pharmaceutical Product
 Table 80. Chinese Peptide Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 81. Chinese Peptide Recent Development
 Table 82. Csbio Company Details
 Table 83. Csbio Business Overview
 Table 84. Csbio Peptide CDMO Pharmaceutical Product
 Table 85. Csbio Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 86. Csbio Recent Development
 Table 87. Corden Pharma Company Details
 Table 88. Corden Pharma Business Overview
 Table 89. Corden Pharma Peptide CDMO Pharmaceutical Product
 Table 90. Corden Pharma Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 91. Corden Pharma Recent Development
 Table 92. Polypeptide Company Details
 Table 93. Polypeptide Business Overview
 Table 94. Polypeptide Peptide CDMO Pharmaceutical Product
 Table 95. Polypeptide Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 96. Polypeptide Recent Development
 Table 97. Hybio Pharmaceutical Company Details
 Table 98. Hybio Pharmaceutical Business Overview
 Table 99. Hybio Pharmaceutical Peptide CDMO Pharmaceutical Product
 Table 100. Hybio Pharmaceutical Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 101. Hybio Pharmaceutical Recent Development
 Table 102. Peptide Institute Company Details
 Table 103. Peptide Institute Business Overview
 Table 104. Peptide Institute Peptide CDMO Pharmaceutical Product
 Table 105. Peptide Institute Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 106. Peptide Institute Recent Development
 Table 107. Pepscan Company Details
 Table 108. Pepscan Business Overview
 Table 109. Pepscan Peptide CDMO Pharmaceutical Product
 Table 110. Pepscan Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 111. Pepscan Recent Development
 Table 112. Almac Company Details
 Table 113. Almac Business Overview
 Table 114. Almac Peptide CDMO Pharmaceutical Product
 Table 115. Almac Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 116. Almac Recent Development
 Table 117. Vivitide Company Details
 Table 118. Vivitide Business Overview
 Table 119. Vivitide Peptide CDMO Pharmaceutical Product
 Table 120. Vivitide Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 121. Vivitide Recent Development
 Table 122. Creosalus Inc Company Details
 Table 123. Creosalus Inc Business Overview
 Table 124. Creosalus Inc Peptide CDMO Pharmaceutical Product
 Table 125. Creosalus Inc Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 126. Creosalus Inc Recent Development
 Table 127. Scinopharm Company Details
 Table 128. Scinopharm Business Overview
 Table 129. Scinopharm Peptide CDMO Pharmaceutical Product
 Table 130. Scinopharm Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 131. Scinopharm Recent Development
 Table 132. Senn Chemicals Company Details
 Table 133. Senn Chemicals Business Overview
 Table 134. Senn Chemicals Peptide CDMO Pharmaceutical Product
 Table 135. Senn Chemicals Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 136. Senn Chemicals Recent Development
 Table 137. Belyntic Company Details
 Table 138. Belyntic Business Overview
 Table 139. Belyntic Peptide CDMO Pharmaceutical Product
 Table 140. Belyntic Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 141. Belyntic Recent Development
 Table 142. Ferring Pharma Company Details
 Table 143. Ferring Pharma Business Overview
 Table 144. Ferring Pharma Peptide CDMO Pharmaceutical Product
 Table 145. Ferring Pharma Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 146. Ferring Pharma Recent Development
 Table 147. Numaferm Company Details
 Table 148. Numaferm Business Overview
 Table 149. Numaferm Peptide CDMO Pharmaceutical Product
 Table 150. Numaferm Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 151. Numaferm Recent Development
 Table 152. Hybio Pharmaceutical Company Details
 Table 153. Hybio Pharmaceutical Business Overview
 Table 154. Hybio Pharmaceutical Peptide CDMO Pharmaceutical Product
 Table 155. Hybio Pharmaceutical Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 156. Hybio Pharmaceutical Recent Development
 Table 157. Provepharm Life Solutions Company Details
 Table 158. Provepharm Life Solutions Business Overview
 Table 159. Provepharm Life Solutions Peptide CDMO Pharmaceutical Product
 Table 160. Provepharm Life Solutions Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 161. Provepharm Life Solutions Recent Development
 Table 162. Enzene Biosciences Company Details
 Table 163. Enzene Biosciences Business Overview
 Table 164. Enzene Biosciences Peptide CDMO Pharmaceutical Product
 Table 165. Enzene Biosciences Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 166. Enzene Biosciences Recent Development
 Table 167. Piramal Pharma Company Details
 Table 168. Piramal Pharma Business Overview
 Table 169. Piramal Pharma Peptide CDMO Pharmaceutical Product
 Table 170. Piramal Pharma Revenue in Peptide CDMO Pharmaceutical Business (2020-2025) & (US$ Million)
 Table 171. Piramal Pharma Recent Development
 Table 172. Research Programs/Design for This Report
 Table 173. Key Data Information from Secondary Sources
 Table 174. Key Data Information from Primary Sources
 Table 175. Authors List of This Report


List of Figures
 Figure 1. Peptide CDMO Pharmaceutical Picture
 Figure 2. Global Peptide CDMO Pharmaceutical Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Peptide CDMO Pharmaceutical Market Share by Type: 2024 VS 2031
 Figure 4. Liquid-phase Peptide Synthesis（LPPS） Features
 Figure 5. Solid-phase Peptide Synthesis（SPPS） Features
 Figure 6. Mixed Phase Features
 Figure 7. Global Peptide CDMO Pharmaceutical Market Size by Application (2020-2031) & (US$ Million)
 Figure 8. Global Peptide CDMO Pharmaceutical Market Share by Application: 2024 VS 2031
 Figure 9. Peptide Supplements Case Studies
 Figure 10. Peptide Vaccines Case Studies
 Figure 11. Others Case Studies
 Figure 12. Peptide CDMO Pharmaceutical Report Years Considered
 Figure 13. Global Peptide CDMO Pharmaceutical Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 14. Global Peptide CDMO Pharmaceutical Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Peptide CDMO Pharmaceutical Market Share by Region: 2024 VS 2031
 Figure 16. Global Peptide CDMO Pharmaceutical Market Share by Players in 2024
 Figure 17. Global Top Peptide CDMO Pharmaceutical Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide CDMO Pharmaceutical as of 2024)
 Figure 18. The Top 10 and 5 Players Market Share by Peptide CDMO Pharmaceutical Revenue in 2024
 Figure 19. North America Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. North America Peptide CDMO Pharmaceutical Market Share by Country (2020-2031)
 Figure 21. United States Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Canada Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Peptide CDMO Pharmaceutical Market Share by Country (2020-2031)
 Figure 25. Germany Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. France Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. U.K. Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Italy Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Russia Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Nordic Countries Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Peptide CDMO Pharmaceutical Market Share by Region (2020-2031)
 Figure 33. China Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Japan Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. South Korea Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Southeast Asia Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. India Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Australia Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Peptide CDMO Pharmaceutical Market Share by Country (2020-2031)
 Figure 41. Mexico Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Brazil Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Peptide CDMO Pharmaceutical Market Share by Country (2020-2031)
 Figure 45. Turkey Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Saudi Arabia Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. UAE Peptide CDMO Pharmaceutical Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Ambiopharm Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 49. Auspep Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 50. Bachem Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 51. Bcn Peptide Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 52. Cpc Scientific Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 53. Creative Peptides Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 54. Chinese Peptide Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 55. Csbio Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 56. Corden Pharma Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 57. Polypeptide Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 58. Hybio Pharmaceutical Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 59. Peptide Institute Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 60. Pepscan Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 61. Almac Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 62. Vivitide Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 63. Creosalus Inc Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 64. Scinopharm Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 65. Senn Chemicals Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 66. Belyntic Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 67. Ferring Pharma Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 68. Numaferm Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 69. Hybio Pharmaceutical Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 70. Provepharm Life Solutions Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 71. Enzene Biosciences Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 72. Piramal Pharma Revenue Growth Rate in Peptide CDMO Pharmaceutical Business (2020-2025)
 Figure 73. Bottom-up and Top-down Approaches for This Report
 Figure 74. Data Triangulation
 Figure 75. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

Pharmaceutical CDMO Pharmaceutical Contract Development and Manufacturing Organization Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Cellular and Gene Therapy CDMO Market Research Report 2025
Constrained Peptide Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Peptide Drug Conjugates Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Peptide Drug CDMO Market Research Report 2024
Contract Research Organization CRO and CDMO for Pharmaceutical Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Pharmacogenomics Technology Theranostics Companion Diagnostics CDx Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Digital Health and Digital Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Prescription Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Pharmaceutical CRDMO Service Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Digital Pharma Knowledge Management Software Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Generic Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
HIV Medicines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Biologics Clinical Manufacturing CDMO Service Market Research Report 2024
High density Multiplexed Diagnostic Assays Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
AI for Cancer Diagnosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Diabetic Retinopathy Fundus Image assisted Diagnosis Software Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Pharmaceutical Asset Managements Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Biopharmaceutical CMO CRO Market
Marine Biopharmaceutical Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-14Y6812
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34O3983
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9V17601
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22C17047
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions